Abstract
Hematopoietic stem cell transplantation (HSCT) was used in childhood leukemia for over 30 years. In comparison with chemotherapy, the HSCT benefit, in the early, mainly consisted of human leukocyte antigen (HLA) matched sibling donor (MSD) had not been proven, especially in acute lymphocytic leukemia. As improving and applying of HLA typing high-resolution technology, the survival in HSCT from unrelated donor already closed to those from MSD transplant, and the reducing of relapse rate has been seen. Regarding to haploidentical transplant, the result has been improving with advances in methodology, the applying has been expanding, and the long-term following up is going on. Cell therapy has showed exciting outcomes. Key words: Hematopoietic stem cell transplantation; Leukemia; Child
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
